Eye Meds Now

 Quick Ophthalmic Drug Search

227 items found
PHOSPHOLINE IODIDE (echothiophate iodide (0.125%) for ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Miotics
Indications/Usage:

Indicated for the reduction of elevated IOP. Also used in concomitant esotropias with a significant accomodative component.


Typical Dosing:  

►Elevated IOP:

  • Instill 1 drop twice a day, just before retiring and in the morning. A change in therapy is indicated if, at any time, the tension fails to remain at an acceptable level on this regimen.
  • 2 doses a day are preferred to 1 in order to maintain as smooth a diurnal tension curve as possible, although a single dose per day or every other day has been used with satisfactory results.
  • The daily dose or one of the two daily doses should always be instilled just before retiring to avoid inconvenience due to the miosis.
  • Technique: Technique in the administration of echothiophate iodide for ophthalmic solution may include finger pressure at the inner canthus exerted for a minute or 2 following instillation of the eyedrops, to potentially minimize drainage into the nose and throat. Excess solution around the eye should be removed with tissue and any medication on the hands should be rinsed off.

Accommodative esotropia (pediatric use):

  • In diagnosis: 1 drop may be instilled once a day in both eyes on retiring, for a period of 2 or 3 weeks. If the esotropia is accommodative, a favorable response will usually be noted which may begin within a few hours.
  • In treatment: Echothiophate iodide for ophthalmic solution is prescribed at the lowest frequency which gives satisfactory results. After the initial period of treatment for diagnostic purposes, the schedule may be reduced to 1 drop every other day. The maximum usually recommended dosage is 1 drop once a day, although more intensive therapy has been used for short periods.
  • Technique: Same as technique for glaucoma above.
  • Duration of treatment: In therapy, there is no definite limit so long as the drug is well tolerated. However, if the eyedrops, with or without eyeglasses, are gradually withdrawn after about a year or 2 and deviation recurs, surgery should be considered. As with other miotics, tolerance may occasionally develop after prolonged use. In such cases, a rest period will restore the original activity of the drug.

DIRECTIONS FOR PREPARING EYEDROPS:

  • Use aseptic technique.
  • Tear off aluminum seals, and remove and discard rubber plugs from both drug and diluent containers.
  • Pour diluent into drug container.
  • Remove dropper assembly from its sterile wrapping. Holding dropper assembly by the screw cap and, WITHOUT COMPRESSING RUBBER BULB, insert into drug container and screw down tightly.
  • Shake for several seconds to ensure mixing.
  • Do not cover nor obliterate instructions to patient regarding storage of eyedrops.

How Supplied:  
  • 6.25 mg/5 mL (0.125%) package with sterile echothiophate iodide for ophthalmic solution, sterile diluent, and dropper for dispensing 5 mL eyedrops.

Preservatives:  

chlorobutanol


Storage:  
  • Prior to reconstitution:
    • Store under refrigeration 36° – 46°F (2° – 8°C).
  • After reconstitution:
    • Store at room temperature (approximately 77°F or 25°C).
    • Do not refrigerate.
    • Discard any unused solution after 4 weeks.


Assistance: Payment Assistance

PHOTREXA (riboflavin 5’-phosphate (0.146%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Other Medications
Indications/Usage:

Indicated for use in corneal collagen cross-linking in combination with the KXL™ System for the treatment of progressive keratoconus or corneal ectasia following refractive surgery.


Typical Dosing:  

Corneal collagen cross-linking in combination with the KXL System for the treatment of progressive keratoconus or corneal ectasia following refractive surgery:

  • Using topical anesthesia, debride the epithelium to a diameter of approximately 9 mm using standard aseptic technique. Post epithelial debridement, instill 1 drop of PHOTREXA VISCOUS topically on the eye every 2 minutes for 30 minutes.
  • At the end of the 30 minute soaking period, examine the eye under the slit lamp for the presence of a yellow flare in the anterior chamber. If the yellow flare is not detected, instill 1 drop of PHOTREXA VISCOUS every 2 minutes for an additional 2 – 3 drops and recheck for the presence of a yellow flare. This process can be repeated as necessary.
  • Once the yellow flare is observed, perform ultrasound pachymetry. If corneal thickness is less than 400 microns, instill 2 drops of PHOTREXA every 5 – 10 seconds until the corneal thickness increases to at least 400 microns. Irradiation should not be performed unless this 400 micron threshold is met and the yellow flare is seen.
  • Irradiate the eye for 30 continuous minutes at 3mW/cm2 at a wavelength of 365 nm, centered over the cornea, using the KXL System as per the instructions in the KXL manual. During irradiation, continue topical instillation of PHOTREXA VISCOUS onto the eye every 2 minutes for the 30 minute irradiation period.
  • For topical ophthalmic use. Do not inject.
  • Single use PHOTREXA VISCOUS and PHOTREXA only. Discard syringe(s) after use.
  • PHOTREXA VISCOUS and PHOTREXA are for use with the KXL System only.
  • PLEASE REFER TO THE KXL OPERATOR’S MANUAL FOR SPECIFIC DEVICE INSTRUCTIONS.

How Supplied:  
  • Photrexa:
    • 3 mL prefilled syringes for use with KXL System
    • Each syringe contains 1.46 mg/mL riboflavin 5-phosphate ophthalmic solution for topical administration
  • Photrexa Viscous:
    • 3 mL prefilled syringes for use with KXL System
    • Each syringe contains 1.56 mg/mL riboflavin 5-phosphate in 20% dextran ophthalmic solution for topical administration

Preservatives:  

None listed in package insert.


Storage:  
  • The entire bulk pack should be stored at 59°– 77°F (15° – 25°C) and care should be taken to minimize exposure of the syringe to light once removed from its protective packaging.
  • Discard syringe after use.
  • For topical ophthalmic use.
  • Should be used with the KXL System only.


Assistance: Payment Assistance

Special Purchasing Instructions: How to Purchase

PILOCARPINE (pilocarpine hydrochloride (1%; 2%; 4%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Miotics
Indications/Usage:

Indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; management of acute angle-closure glaucoma; prevention of post-operative elevated IOP associated with laser surgery and induction of miosis.


Typical Dosing:  

Elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension:

  • 1 drop (1%, 2%, or 4% solution) applied topically in the eye(s) up to 4 times daily. Pilocarpine-naïve patients should be started on the 1% concentration as higher concentrations are often not tolerated initially. The frequency of instillation and concentration of pilocarpine hydrochloride ophthalmic solution 1% are determined by the severity of the elevated IOP and miotic response of the patient.
  • To limit systemic exposure to pilocarpine, patients may be instructed to perform punctal occlusion for 2 minutes after instillation of pilocarpine hydrochloride ophthalmic solution.

Acute angle-closure glaucoma, initial management:

  • Prior to pilocarpine hydrochloride use, treatment with secretory suppressants and hyperosmotic agents may be needed to lower IOP below 50 mmHg and relieve iris ischemia. 
  • Apply 1 drop (1% or 2% solution) topically in the eye(s) up to 3 times over a 30-minute period.
  • If laser iridoplasty or iridomy is used to break the attack, 1 drop of pilocarpine hydrochloride ophthalmic solution 4% should be administered prior to the procedure. Following laser iridoplasty, 1 drop of pilocarpine hydrochloride ophthalmic solution 1% should be administered 4 times daily until an iridotomy can be performed.

Post-operative elevated IOP associated with laser surgery:

  • 1 drop (1%, 2%, or 4% solution) (or 2 drops administered 5 minutes apart) should be applied topically in the eye(s) 15 to 60 minutes prior to surgery.

Miosis:

  • 1 drop (1%, 2%, or 4% solution) (or 2 drops administered 5 minutes apart) should be applied topically in the eye(s).

Use with other topical ophthalmic medications:

  • May be used in combination with beta-blockers, carbonic anhydrase inhibitors, sympathomimetics or hyperosmotic agents. If more than 1 topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.

►Use in pediatric patients:

  • In children < 2 years of age: 
    • Apply 1 drop of 1% solution topically in the eye(s) 3 times daily.
  • Children  2 years of age should be dosed as for adults.
  • For the induction of miosis prior to goniotomy or trabeculotomy in children, 1 drop of pilocarpine hydrochloride ophthalmic solution 1% or 2% should be applied topically in the eye 15 to 60 minutes prior to surgery.

How Supplied:  
  • 1% ophthalmic solution:
    • 15 mL bottles
  • 2% ophthalmic solution:
    • 15 mL bottles
  • 4% ophthalmic solution:
    • 15 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 59° – 77°F (15° – 25°C).
  • Protect from freezing.


POLYCIN (bacitracin zinc (500 units/g) – polymyxin B sulfate (10,000 units/g) ophthalmic ointment)
Prescription
Topical
Ointment
Antibiotics
Indications/Usage:

Indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis.

This medication has a broad FDA approval for "superficial infections of the external eye and its adnexa." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "superficial infections of the external eye and its adnexa." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

Superficial infections of the external eye and its adnexa caused by susceptible bacteria:

  • May be applied every 3 or 4 hours for 7 – 10 days, depending on the severity of the infection.

How Supplied:  
  •  3.5 g tubes

Preservatives:  

None listed in package insert.


Storage:  
  • Store at 68° – 77°F (20° – 25°C).


POLYTRIM (trimethoprim sulfate (0.1%) – polymyxin B sulfate (10,000 units/mL) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Antibiotics
Indications/Usage:

Indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis and blepharoconjunctivitis caused by susceptible strains of the following microorganisms: Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus pneumoniae; Streptococcus viridan; Haemophilus influenzae; Pseudomonas aeruginosa*.

*Efficacy for this organism in this organ system was studied in fewer than 10 infections.

This medication has a broad FDA approval for "surface ocular bacterial infections." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "surface ocular bacterial infections." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

Mild to moderate surface ocular bacterial infections:

  • Instill 1 drop in the affected eye(s) every 3 hours (maximum of 6 doses per day) for a period of 7 – 10 days.

How Supplied:  
  • 10  mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 59˚ – 77˚F (15˚ – 25˚C).
  • Protect from light.


PRED FORTE (prednisolone acetate (1%) ophthalmic suspension)
Prescription
Topical
Ophthalmic Suspension
Allergy Corticosteroids, Anti-inflammatory Corticosteroids
Indications/Usage:

Indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.

This medication has a broad FDA approval for "steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

Steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe:

  • Shake well before using.  
  • Instill 1 – 2 drops into the conjunctival sac 2 – 4 times daily. During the initial 24 – 48 hours, the dosing frequency may be increased if necessary.
  • Care should be taken not to discontinue therapy prematurely.
  • If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated (See PRECAUTIONS in package insert).

How Supplied:  
  • 5 mL bottles
  • 10 mL bottles
  • 15 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at temperatures up to 77°F (25°C).
  • Protect from freezing.
  • Store in an upright position.


Assistance: Payment Assistance

PRED MILD (prednisolone acetate (0.12%) ophthalmic suspension)
Prescription
Topical
Ophthalmic Suspension
Allergy Corticosteroids, Anti-inflammatory Corticosteroids
Indications/Usage:

Indicated for the treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea and sclera (including chemical and thermal burns).

This medication has a broad FDA approval for "mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea and sclera." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea and sclera." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

Mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea and sclera (including chemical and thermal burns):

  • Shake well before using.
  • Instill 1 – 2 drops into the conjunctival sac 2  4 times daily. During the initial 24 – 48 hours, the dosing frequency may be increased if necessary.
  • Care should be taken not to discontinue therapy prematurely.
  • If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated (See PRECAUTIONS in package insert).

How Supplied:  
  • 5 mL bottles
  • 10 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 59° – 86°F (15° – 30°C).
  • Store in an upright position.
  • Protect from freezing.


PRED-G (gentamicin (0.3%) – prednisolone acetate (0.6%; 1%) ophthalmic ointment; ophthalmic suspension)
Prescription
Topical
Ointment
Ophthalmic Suspension
Antibiotic–Steroid Combination Medications
Indications/Usage:

Indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.

Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns or penetration of foreign bodies.

The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye.

The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus; Streptococcus pyogenes; Streptococcus pneumoniae; Enterobacter aerogenes; Escherichia coli; Haemophilus influenzae; Klebsiella pneumoniae; Neisseria gonorrhoeae; Pseudomonas aeruginosa; Serratia marcescens.

This medication has a broad FDA approval for "inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

Steroid-responsive inflammatory ocular conditions:

  • Ophthalmic ointment:
    • A small amount (½ inch ribbon) of ointment should be applied in the conjunctival sac 1 – 3 times daily.
    • Care should be taken not to discontinue therapy prematurely.
    • If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated (See PRECAUTIONS in package insert).
    • Not more than 8 g should be prescribed initially and the prescription should not be refilled without further evaluation.
  • Ophthalmic suspension:
    • Instill 1 drop into the conjunctival sac 2 – 4 times daily. During the initial 24 – 48 hours, the dosing frequency may be increased, if necessary, up to 1 drop every hour.
    • Care should be taken not to discontinue therapy prematurely.
    • If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated (See PRECAUTIONS in package insert).
    • Not more than 20 mL should be prescribed initially, and the prescription should not be refilled without further evaluation.

How Supplied:  
  • Ophthalmic ointment:
    • 3.5 g tubes
  • Ophthalmic suspension:
    • 5 mL bottles

Preservatives:  

chlorobutanol (ophthalmic ointment); benzalkonium chloride (ophthalmic suspension)


Storage:  
  • Store at 59° – 77°F (15° – 25°C).
  • Avoid excessive heat, 104°F (40°C) and above.
  • Protect from freezing.
  • Shake ophthalmic suspension well before using.


PREDNISOLONE SODIUM PHOSPHATE (prednisolone sodium phosphate (1%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Allergy Corticosteroids, Anti-inflammatory Corticosteroids
Indications/Usage:

Indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation, corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies.

Recommended for moderate to severe inflammations, particularly when unusually rapid control is desired. In stubborn cases of anterior segment eye disease, systemic adrenocortical hormone therapy may be required. When deeper ocular structures are involved, systemic therapy is necessary.

This medication has a broad FDA approval for "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe:

  • Depending on the severity of inflammation, instill 1 or 2 drops of solution into the conjunctival sac up to every hour during the day and every 2 hours during the night as necessary as initial therapy. 
  • When a favorable response is observed, reduce dosage to 1 drop every 4 hours.
  • Later, further reduction in dosage to 1 drop 3 – 4 times daily may suffice to control symptoms.
  • The duration of treatment will vary with the type of lesion and may extend from a few days to several weeks, according to therapeutic response. Relapses, more common in chronic active lesions than in self-limited conditions, usually respond to retreatment.

How Supplied:  
  • 10 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store between 59° – 77°F (15° – 25°C).
  • Protect from light.
  • Keep tightly closed.
  • DO NOT USE IF IMPRINTED NECKBAND IS NOT INTACT.
  • KEEP OUT OF REACH OF CHILDREN.


PREDNISONE (prednisone (1 mg; 2.5 mg; 5 mg; 10 mg; 20 mg; 50 mg) tablets)
Prescription
Oral
Tablets
Allergy Corticosteroids, Anti-inflammatory Corticosteroids
Indications/Usage:

Indicated in severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: allergic corneal marginal ulcers; herpes zoster ophthalmicus; anterior segment inflammation; diffuse posterior uveitis and choroiditis; sympathetic ophthalmia; allergic conjunctivitis; keratitis chorioretinitis; optic neuritis; iritis and iridocyclitis.

This medication has a broad FDA approval for "severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa:

  • The initial dosage of prednisone may vary from 5 mg – 60 mg per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there is a lack of satisfactory clinical response, prednisone should be discontinued and the patient transferred to other appropriate therapy. 
  • IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT. 
  • After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached.
  • It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment; in this latter situation it may be necessary to increase the dosage of prednisone for a period of time consistent with the patient’s condition.
  • If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.
  • Consult package insert for additional information.

How Supplied:  
  • Tablets:
    • 1 mg tablets
    • 2.5 mg tablets
    • 5 mg tablets
    • 10 mg tablets
    • 20 mg tablets
    • 50 mg tablets

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 68° – 77°F (20° – 25°C).
  • Protect from moisture.


PROLENSA (bromfenac sodium (0.07%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
NSAIDS
Indications/Usage:

Indicated for the treatment of post-operative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.


Typical Dosing:  

Post-operative inflammation and reduction of ocular pain in patients who have undergone cataract surgery, recommended:

  • 1 drop should be applied to the affected eye once daily beginning 1 day prior to cataract surgery,​​​​​​ continued on the day of surgery, and through the first 14 days of the post-operative period.
  • Use with other topical ophthalmic medications:
    • May be administered in conjunction with other topical ophthalmic medications such as alpha-agonists, beta-blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics.
    • Drops should be administered at least 5 minutes apart.

How Supplied:  
  • 3 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 59º – 77ºF (15º – 25ºC).


Assistance: Payment Assistance

PROPARACAINE HYDROCHLORIDE (proparacaine hydrochloride (0.5%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Anesthetic Medications
Indications/Usage:

Indicated for procedures in which a topical ophthalmic anesthetic is indicated: corneal anesthesia of short duration, e.g. tonometry, gonioscopy, removal of corneal foreign bodies, and for short corneal and conjunctival procedures.


Typical Dosing:  

Removal of foreign bodies and sutures, and for tonometry, usual dosage:

  • 1 – 2 drops (in single instillations) in each eye before operating.

Short corneal and conjunctival procedures, usual dosage:

  • 1 drop in each eye every 5 – 10 minutes for 5 – 7 doses.

 Proparacaine hydrochloride ophthalmic solution should be clear to straw-color. If the solution becomes darker, discard the solution.


How Supplied:  
  • 15 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store bottles in unit cartons to protect contents from light.
  • Store bottles under refrigeration at 36° – 46°F (2°– 8°C).


RESTASIS (cyclosporine (0.05%) ophthalmic emulsion)
Prescription
Topical
Emulsion
Immunosuppressants/Immunomodulators
Indications/Usage:

Indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.


Typical Dosing:  

Tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca:

  • Unit-dose vials:
    • Invert the unit-dose vial a few times to obtain a uniform, white, opaque emulsion before using.
    • Instill 1 drop twice a day in each eye approximately 12 hours apart.
    • Can be used concomitantly with lubricant eye drops, allowing a 15 minute interval between products.
    • Discard vial immediately after use.
  • Multi-dose bottle:
    • Turn the bottle upside down a few times before giving your dose to make sure the medicine is mixed well.
    • Instill 1 drop twice a day in each eye approximately 12 hours apart.
    • Replace the olive green colored protective cap.
    • Can be used concomitantly with lubricant eye drops, allowing a 15 minute interval between products.
  • Consult package insert for information on preparation for use.

How Supplied:  
  • Unit dose vials:
    • 5 vials in 1 carton (0.4 mL per vial)
    • 30 vials in 1 tray (0.4 mL per vial)
    • 60 vials in 1 tray (0.4 mL per vial)
  • Multi dose bottle:
    • 5.5 mL bottles

Preservatives:  

None listed in package insert.


Storage:  
  • Store at 59° – 77°F (15° – 25°C).


Assistance: Payment Assistance

RETISERT (fluocinolone acetonide (0.59 mg) intravitreal implant )
Prescription
Injectable
Intravitreal
Anti-inflammatory Corticosteroids
Indications/Usage:

Indicated for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye.


Typical Dosing:  

Chronic noninfectious uveitis affecting the posterior segment of the eye:

  • RETISERT® (fluocinolone acetonide intravitreal implant) 0.59 mg is implanted into the posterior segment of the affected eye through a pars plana incision.
  • The implant contains 1 tablet of 0.59 mg of fluocinolone acetonide. RETISERT® is designed to release fluocinolone acetonide at a nominal initial rate of 0.6 mcg/day, decreasing over the first month to a steady state between 0.3 – 0.4 mcg/day over approximately 30 months. Following depletion of fluocinolone acetonide as evidenced by recurrence of uveitis, RETISERT® may be replaced.
  • Additional information for Dosage and Administration is in Notes below.

How Supplied:  
  • 0.59 mg implants (each approximately 3 mm x 2 mm x 5 mm)

Preservatives:  

None listed in package insert.


Storage:  
  • Store in the original container at 59° – 77°F (15° – 25°C).
  • Protect from freezing.


Assistance: Payment Assistance

RHOPRESSA (netarsudil (0.02%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Rho Kinase Inhibitors
Indications/Usage:

Indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.


Typical Dosing:  

Elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, recommended:

  • 1 drop in the affected eye(s) once daily in the evening.
  • If 1 dose is missed, treatment should continue with the next dose in the evening.
  • Twice a day dosing is not well tolerated and is not recommended.
  • If RHOPRESSA is to be used concomitantly with other topical ophthalmic drug products to lower IOP, administer each drug product at least 5 minutes apart [See Patient Counseling Information (17) in package insert].

How Supplied:  
  • 2.5 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 36° – 46°F (2° – 8°C) until opened.
  • After opening, the product may be kept at 36° – 77°F (2° – 25°C) for up to 6 weeks.
  • If after opening the product is kept refrigerated at 36° – 46°F (2° – 8°C), then the product can be used until the expiration date stamped on the bottle.


Assistance: Payment Assistance

ROCKLATAN (netarsudil (0.02%) – latanoprost (0.005%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Combinations
Indications/Usage:

Indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.


Typical Dosing:  

►Glaucoma, open-angle or ocular hypertension, recommended:

  • 1 drop in the affected eye(s) once daily in the evening.
  • If 1 dose is missed, treatment should continue with the next dose in the evening. The dosage of ROCKLATAN should not exceed once daily.
  • ROCKLATAN may be used concomitantly with other topical ophthalmic drug products to lower IOP.
  • If more than 1 topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.

How Supplied:  
  • 2.5 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 36° – 46°F (2° – 8°C).
  • Protect from light.
  • After opening, ROCKLATAN can be used until the expiration date on the bottle.


Assistance: Payment Assistance

SIMBRINZA (brinzolamide (1%) – brimodine tartrate (0.2%) ophthalmic suspension)
Prescription
Topical
Ophthalmic Suspension
Combinations
Indications/Usage:

Indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.


Typical Dosing:  

Elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, recommended:

  • Shake well before use.
  • Instill 1 drop in the affected eye(s) 3 times daily.
  • May be used concomitantly with other topical ophthalmic drug products to lower IOP. 
  • If more than 1 topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.

How Supplied:  
  • 8 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 36° – 77°F (2° – 25°C).


Assistance: Payment Assistance

SOCHLOR (sodium chloride (5%) ophthalmic ointment; ophthalmic solution)
Over the Counter
Topical
Ointment
Ophthalmic Solution
Hyperosmotic Medications
Indications/Usage:

Used for the temporary relief of corneal edema as an eye lubricant.


Typical Dosing:  

Corneal edema:

  • Ophthalmic ointment:
    • Apply a small amount (¼ inch) to the inside of the affected eye(s) every 3 – 4 hours, or as directed by a doctor.
  • Ophthalmic solution:
    • Instill 1 – 2 drops in the affected eye(s) every 3 – 4 hours, or as directed by a doctor.

How Supplied:  
  • Ophthalmic ointment:
    • 3.5 g tubes (generic only)
  • Ophthalmic solution:
    • 15 mL bottles

Preservatives:  

None listed in package insert (ophthalmic ointment); methylparaben, polyparaben (ophthalmic solution)


Storage:  
  • Store at room temperature 59° – 86°F (15° – 30°C).
  • Keep from freezing.
  • Keep tightly closed.
  • See crimp of tube or box for ointment lot number and expiration date.


SODIUM CHLORIDE (sodium chloride (5%) ophthalmic ointment; ophthalmic solution)
Over the Counter
Topical
Ointment
Ophthalmic Solution
Hyperosmotic Medications
Indications/Usage:

Indicated for temporary relief of corneal edema.


Typical Dosing:  

Corneal edema:

  • Ophthalmic ointment:
    • Apply small amount (¼ inch) to the inside of affected eye(s) every 3  4 hours, or as directed by a doctor.
  • Ophthalmic solution:
    • Instill 1   2 drops in the affected eye(s) as needed.

How Supplied:  
  • Ophthalmic ointment:
    • 3.5 g tubes
  • Ophthalmic solution:
    • 15 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 68° – 77°F (20° – 25°C).
  • Store away from heat.
  • Protect from freezing.
  • Keep tightly closed.
  • See crimp on ointment tube for control number and expiration date.


TEPEZZA (teprotumumab-trbw (500 mg) powder for reconstitution and injection)
Prescription
Injectable
IV
Other Medications
Indications/Usage:

Indicated for the treatment of thyroid eye disease.


Typical Dosing:  

Thyroid eye disease, recommended:

  • Intravenous infusion of 10 mg/kg for the initial dose followed by an intravenous infusion of 20 mg/kg every 3 weeks for 7 additional infusions.
  • Dilute solution as described in package insert or in Notes below.
  • Administration:
    • Administer the diluted solution intravenously over 90 minutes for the first 2 infusions. If well tolerated, the minimum time for subsequent infusions can be reduced to 60 minutes. If not well tolerated, the minimum time for subsequent infusions should remain at 90 minutes.
    • Do not administer as an intravenous push or bolus. TEPEZZA should not be infused concomitantly with other agents.
  • Additional information for Reconstitution and Preparation is in Notes below.

How Supplied:  
  • 500 mg single dose vials
    • white to off-white lyophilized powder for reconstitution and dilution

Preservatives:  

None listed in package insert.


Storage:  
  • Refrigerate at 36° – 46°F (2° – 8°C).
  • Store in original carton until time of use to protect from light.
  • Do not freeze.


Special Purchasing Instructions: How to Purchase

227 items found